129 related articles for article (PubMed ID: 28031082)
1. Association Between Geranylgeranyl Pyrophosphate Synthase Gene Polymorphisms and Bone Phenotypes and Response to Alendronate Treatment in Chinese Osteoporotic Women.
Han LW; Ma DD; Xu XJ; Lü F; Liu Y; Xia WB; Jiang Y; Wang O; Xing XP; Li M
Chin Med Sci J; 2016 Mar; 31(1):8-16. PubMed ID: 28031082
[TBL] [Abstract][Full Text] [Related]
2. Association of farnesyl diphosphate synthase polymorphisms and response to alendronate treatment in Chinese postmenopausal women with osteoporosis.
Liu Y; Liu H; Li M; Zhou P; Xing X; Xia W; Zhang Z; Liao E; Chen D; Liu J; Tao T; Wu W; Xu L
Chin Med J (Engl); 2014; 127(4):662-8. PubMed ID: 24534219
[TBL] [Abstract][Full Text] [Related]
3. LRP5 polymorphisms and response to alendronate treatment in Chinese postmenopausal women with osteoporosis.
Zhou PR; Liu HJ; Liao EY; Zhang ZL; Chen DC; Liu J; Wu W; Xing XP; Xia WB; Xu L; Li M
Pharmacogenomics; 2014 Apr; 15(6):821-31. PubMed ID: 24897288
[TBL] [Abstract][Full Text] [Related]
4. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
[TBL] [Abstract][Full Text] [Related]
5. The analysis of DKK1 polymorphisms in relation to skeletal phenotypes and bone response to alendronate treatment in Chinese postmenopausal women.
Wang JY; Zhou PR; Liu Y; Xu XJ; Ma DD; Xia WB; Jiang Y; Wang O; Xing XP; Li M
Pharmacogenomics; 2016 Feb; 17(3):209-17. PubMed ID: 26780085
[TBL] [Abstract][Full Text] [Related]
6. SOST polymorphisms and response to alendronate treatment in postmenopausal Chinese women with osteoporosis.
Zhou PR; Xu XJ; Zhang ZL; Liao EY; Chen DC; Liu J; Wu W; Jiang Y; Wang O; Xia WB; Xing XP; Xu L; Li M
Pharmacogenomics; 2015; 16(10):1077-88. PubMed ID: 26250343
[TBL] [Abstract][Full Text] [Related]
7. OPG, RANKL, and RANK gene polymorphisms and the bone mineral density response to alendronate therapy in postmenopausal Chinese women with osteoporosis or osteopenia.
Zheng H; Wang C; He JW; Fu WZ; Zhang ZL
Pharmacogenet Genomics; 2016 Jan; 26(1):12-9. PubMed ID: 26426211
[TBL] [Abstract][Full Text] [Related]
8. Transforming growth factor-beta1 gene polymorphisms and bone turnover, bone mineral density and fracture risk in southern Chinese women.
Lau HH; Ho AY; Luk KD; Kung AW
Calcif Tissue Int; 2004 Jun; 74(6):516-21. PubMed ID: 15354859
[TBL] [Abstract][Full Text] [Related]
9. Determinants of one-year response of lumbar bone mineral density to alendronate treatment in elderly Japanese women with osteoporosis.
Iwamoto J; Takeda T; Sato Y; Uzawa M
Yonsei Med J; 2004 Aug; 45(4):676-82. PubMed ID: 15344210
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of recombinant human parathyroid hormone (1-34) are similar to those of alendronate in the treatment of postmenopausal osteoporosis.
Deng J; Feng Z; Li Y; Pan T; Li Q; Zhao C
Medicine (Baltimore); 2018 Nov; 97(47):e13341. PubMed ID: 30461654
[TBL] [Abstract][Full Text] [Related]
11. Differences in the capacity of several biochemical bone markers to assess high bone turnover in early menopause and response to alendronate therapy.
Fink E; Cormier C; Steinmetz P; Kindermans C; Le Bouc Y; Souberbielle JC
Osteoporos Int; 2000; 11(4):295-303. PubMed ID: 10928218
[TBL] [Abstract][Full Text] [Related]
12. Association of PFN1 Gene Polymorphisms with Bone Mineral Density, Bone Turnover Markers, and Osteoporotic Fractures in Chinese Population.
Wu Y; Wu S; Yang E; Zhang G; Shi Q; Liang J; Lian X; Xu J
Calcif Tissue Int; 2023 Aug; 113(2):207-215. PubMed ID: 37401976
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of alendronate once weekly in Asian postmenopausal osteoporotic women.
Ho AY; Kung AW
Ann Pharmacother; 2005 Sep; 39(9):1428-33. PubMed ID: 16076919
[TBL] [Abstract][Full Text] [Related]
14. Effect of alendronate on bone mineral density and bone turnover markers in post-gastrectomy osteoporotic patients.
Iwamoto J; Uzawa M; Sato Y; Takeda T; Matsumoto H
J Bone Miner Metab; 2010 Mar; 28(2):202-8. PubMed ID: 19690798
[TBL] [Abstract][Full Text] [Related]
15. Associations of Serum Cathepsin K and Polymorphisms in
Gao LH; Li SS; Yue H; Zhang ZL
Front Endocrinol (Lausanne); 2020; 11():48. PubMed ID: 32117071
[TBL] [Abstract][Full Text] [Related]
16. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
Burshell AL; Möricke R; Correa-Rotter R; Chen P; Warner MR; Dalsky GP; Taylor KA; Krege JH
Bone; 2010 Apr; 46(4):935-9. PubMed ID: 20060081
[TBL] [Abstract][Full Text] [Related]
17. Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss.
Choi HJ; Im JA; Kim SH
Maturitas; 2008 Jun; 60(2):170-6. PubMed ID: 18572334
[TBL] [Abstract][Full Text] [Related]
18. Differences of therapeutic effects on regional bone mineral density and markers of bone mineral metabolism between alendronate and alfacalcidol in Japanese osteoporotic women.
Takata S; Abbaspour A; Yonezu H; Yasui N
J Med Invest; 2007 Feb; 54(1-2):35-40. PubMed ID: 17380012
[TBL] [Abstract][Full Text] [Related]
19.
Zhao J; Liu L; Lv S; Wang C; Yue H; Zhang Z
Pharmgenomics Pers Med; 2021; 14():1669-1678. PubMed ID: 34992429
[TBL] [Abstract][Full Text] [Related]
20. The efficacy and tolerability of alendronate in postmenopausal osteoporotic Chinese women: a randomized placebo-controlled study.
Kung AW; Yeung SS; Chu LW
Calcif Tissue Int; 2000 Oct; 67(4):286-90. PubMed ID: 11000341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
